From: Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies
Study source | Sex | Study period | Source of subjects | No of case | No of control/cohort size | Cancer site | Exposure assessment | Exposure Definition | Adjustment for covariates | Study quality |
---|---|---|---|---|---|---|---|---|---|---|
Case-control studies | ||||||||||
Risch HA [110], 2017, China | M/F | 2006–2011 | Our Shanghai study | 761 | 794 | Pancreatic cancer | In-person questionnaire interviews | Use at least one tablet per week for 3 months or longer(regular) | 1,2,3,5,7,10,50,51 | 7 |
Kho PF [111], 2016, Australia | M/F | 2007–2011 | The QPCS | 522 | 652 | Pancreatic cancer | Questionnaire | Long-term use of aspirin ((> 2 years) | 1,2,3,6,10 | 8 |
Streicher SA [112], 2014, US | M/F | 2005–2009 | Population from Connecticut | 360 | 682 | Pancreatic cancer | Questionnaire | Use at least once a week on average, for 3 months or more | 1,2,3,5,7,10,11,52 | 8 |
Tan XL [113], 2011, US | M/F | 2004–2010 | Patients from the Mayo Clinic | 740 | 1043 | Pancreatic cancer | Questionnaire | Use aspirin ≥1 day per month | 1,2,3,7,10 | 6 |
Pugh TFG [114], 2011, UK | M/F | 2004–2007 | Clinical management databases in Norfolk and Leicestershire | 206 | 251 | Pancreatic cancer | Medical records | Use of aspirin - not further defined | 1,2,3,7 | 6 |
Bonifazi M [115], 2010, Italy | M/F | 1991–2008 | Patients in in the province of Pordenone and in the greater Milan area, northern Italy | 308 | 477 | Pancreatic cancer | Questionnaire | Use at least once a week for more than 6 months(regular) | 1,2,3,5,7,10,53,54 | 8 |
Menezes RJ [116], 2002, US | M/F | 1982–1998 | The RPCI | 194 | 585 | Pancreatic cancer | Patient Epidemiology Data System (PEDS) and questionnaire | Use at least once a week for six consecutive months(regular) | 1,3,4 | 5 |
Cohort studies | ||||||||||
Cao Y [8], 2016, US | M/F | 1980–2010 1986–2012 | NHS and HPFS | 607 | 135,965 | Pancreatic cancer | Questionnaire | Use at least 2 times per week(regular) | 3,4,6,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24 | 9 |
Brasky TM [92], 2014, US | F | 1998–2010 | WHI | 397 | 142,330 | Pancreatic cancer | Self-administered questionnaires | Use at both baseline and year 3 visits (consistent) | 1,3,4,5, 6,10,11,17,18,19,25,26,28,29,30,31,32,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48 | 9 |
Bradley MC [117], 2010, UKa | M/F | 1995–2006 | GPRD | 564 | 3984 | Pancreatic cancer | Prescription Database | Use 300 mg or more a day (high-dose) | 3,6,7,10, 25,27,47,55, | 8 |
Jacobs EJ [98], 2007, US | M/F | 1992–2003 | Cancer Prevention Study II Nutrition Cohort | 404 | 146,113 | Pancreatic cancer | Questionnaire | Use at least 30 “times” per month(daily use of adult-strength) | 1,2,3,5,7,10,11, 15,16,17,18,20,25, 45, 49 | 8 |
Friis S [62], 2003, Denmarka | M/F | 1989–1997 | Population from North Jutland County | 62 | 29,470 | Pancreatic cancer | Prescription Database | 75–150 mg once daily(low-dose aspirin) | 1,2 | 8 |
Anderson KE [118], 2002, US | F | 1992–1999 | IWHS | 80 | 28,283 | Pancreatic cancer | Questionnaire | Never use any type of medication (never use) | 1,3,7,19 | 7 |
Schreinemachers DM [63], 1994, US | M/F | 1971–1987 | The National Health and Examination Survey Ι | 30 | 12,668 | Pancreatic cancer | Self reported | Use aspirin during the 30-day period before the interview | 1,2 | 6 |